Takayuki Kosaka

11.6k total citations · 3 hit papers
93 papers, 9.3k citations indexed

About

Takayuki Kosaka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Takayuki Kosaka has authored 93 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Takayuki Kosaka's work include Lung Cancer Treatments and Mutations (49 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (14 papers). Takayuki Kosaka is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (14 papers). Takayuki Kosaka collaborates with scholars based in Japan, United States and Australia. Takayuki Kosaka's co-authors include Tetsuya Mitsudomi, Yasushi Yatabe, Hiroyuki Kuwano, Takashi Takahashi, Hideki Endoh, Pasi A. Jänne, Bruce E. Johnson, Toyoaki Hida, Charles Lee and Tony Mok and has published in prestigious journals such as Science, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Takayuki Kosaka

88 papers receiving 9.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

2004 1.0k citations Takayuki Kosaka, Yasushi Yatabe et al. Cancer Research profile →
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 830 citations Tetsuya Mitsudomi, Takayuki Kosaka et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Takayuki Kosaka Japan	32	6.5k	5.6k	3.8k	1.8k	726	93	9.3k
Ross A. Okimoto United States	20	8.1k 1.3×	7.3k 1.3×	4.9k 1.3×	2.7k 1.5×	868 1.2×	33	12.1k
Seiji Yano Japan	46	4.9k 0.8×	5.2k 0.9×	4.3k 1.1×	1.6k 0.9×	629 0.9×	253	9.6k
Daniel B. Costa United States	49	8.4k 1.3×	6.8k 1.2×	3.6k 0.9×	2.2k 1.2×	712 1.0×	169	10.4k
Helena A. Yu United States	41	6.6k 1.0×	5.5k 1.0×	3.1k 0.8×	2.0k 1.1×	591 0.8×	195	8.4k
Hidefumi Sasaki Japan	40	7.3k 1.1×	6.4k 1.1×	5.0k 1.3×	2.7k 1.5×	714 1.0×	143	11.9k
Isamu Okamoto Japan	61	9.4k 1.5×	9.5k 1.7×	4.1k 1.1×	2.0k 1.1×	836 1.2×	383	13.9k
Sara M. Haserlat United States	9	7.0k 1.1×	6.2k 1.1×	3.7k 1.0×	2.3k 1.3×	632 0.9×	10	9.8k
Philip C. Mack United States	44	3.5k 0.5×	3.8k 0.7×	2.9k 0.7×	1.9k 1.1×	633 0.9×	234	6.8k
Rafał Dziadziuszko Poland	44	6.3k 1.0×	5.8k 1.0×	2.7k 0.7×	1.8k 1.0×	557 0.8×	290	9.0k
Jeffrey C. Lee United States	11	5.8k 0.9×	5.1k 0.9×	4.2k 1.1×	2.2k 1.2×	527 0.7×	14	9.4k

Countries citing papers authored by Takayuki Kosaka

Since Specialization

Citations

This map shows the geographic impact of Takayuki Kosaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takayuki Kosaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takayuki Kosaka more than expected).

Fields of papers citing papers by Takayuki Kosaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takayuki Kosaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takayuki Kosaka. The network helps show where Takayuki Kosaka may publish in the future.

Co-authorship network of co-authors of Takayuki Kosaka

This figure shows the co-authorship network connecting the top 25 collaborators of Takayuki Kosaka. A scholar is included among the top collaborators of Takayuki Kosaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takayuki Kosaka. Takayuki Kosaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ibe, Takashi, et al.. (2023). Pulmonary cavernous hemangioma combined with smooth muscle hyperplasia: a case report and review of the literature. PubMed. 2(1). 22–22. 1 indexed citations

Nakazawa, Seshiru, Kimihiro Shimizu, Kai Obayashi, et al.. (2023). Clinicopathological features and surgical outcomes of lobectomy combined with segmentectomy: a cohort study. Journal of Thoracic Disease. 15(3). 1075–1085. 1 indexed citations

Ohtaki, Yoichi, Kyoichi Kaira, Toshiki Yajima, et al.. (2021). Comprehensive expressional analysis of chemosensitivity‐related markers in large cell neuroendocrine carcinoma of the lung. Thoracic Cancer. 12(20). 2666–2679. 4 indexed citations

Jang, Jaebong, Jieun Son, Eunyoung Park, et al.. (2018). Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angewandte Chemie International Edition. 57(36). 11629–11633. 23 indexed citations

Koga, T., Yoshihisa Kobayashi, Kenji Tomizawa, et al.. (2018). Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer. 126. 72–79. 52 indexed citations

Yajima, Toshiki, Akira Mogi, Kimihiro Shimizu, et al.. (2018). Ectopic thymoma in the paratracheal region of the middle mediastinum: a rare case report and literature review. BMC Research Notes. 11(1). 256–256. 8 indexed citations

Takamatsu, Koutaro, Shunya Nakane, Shigeaki Suzuki, et al.. (2018). Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Annals of Clinical and Translational Neurology. 5(11). 1421–1427. 29 indexed citations

Yamashita, Satoshi, et al.. (2018). Cerebrotendinous xanthomatosis presenting with extensive cerebral cortex symptoms: A case report. Clinical Neurology and Neurosurgery. 174. 217–219. 6 indexed citations

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

10.

Chong, Curtis R., Magda Bahcall, Marzia Capelletti, et al.. (2016). Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research. 23(1). 204–213. 67 indexed citations

11.

Kosaka, Takayuki, et al.. (2014). Bow hunter^|^rsquo;s syndrome: Usefulness of carotid ultrasonography and four-dimensional CT angiography. 26(2). 98–101.

12.

Yokobori, Takehiko, Akira Mogi, Hideki Endoh, et al.. (2013). FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs. Molecular Cancer Research. 12(1). 32–37. 47 indexed citations

13.

Tomizawa, Kenji, Kenichi Suda, Ryoichi Onozato, et al.. (2011). Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 74(1). 139–144. 113 indexed citations

14.

Kosaka, Takayuki, Yasushi Yatabe, Ryoichi Onozato, Hiroyuki Kuwano, & Tetsuya Mitsudomi. (2009). Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma. Journal of Thoracic Oncology. 4(1). 22–29. 196 indexed citations

15.

Onozato, Ryoichi, Takayuki Kosaka, Hiroyuki Kuwano, et al.. (2009). Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers. Journal of Thoracic Oncology. 4(1). 5–11. 247 indexed citations

16.

Toyooka, Shinichi, Toshimi Takano, Takayuki Kosaka, et al.. (2008). Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib‐treated patients with lung adenocarcinoma. Cancer Science. 99(2). 303–308. 30 indexed citations

17.

Tanaka, Hisaaki, Kiyoshi Yanagisawa, Keiko Shinjo, et al.. (2007). Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1. Cancer Research. 67(13). 6007–6011. 165 indexed citations

18.

Engelman, Jeffrey A., Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 316(5827). 1039–1043. 3570 indexed citations breakdown →

19.

Toyooka, Shinichi, Akiko Uchida, Hisayuki Shigematsu, et al.. (2007). The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. Journal of Thoracic Oncology. 2(4). 321–324. 2 indexed citations

20.

Onozato, Ryoichi, Takayuki Kosaka, Hiroyuki Achiwa, et al.. (2007). LKB1 gene mutations in Japanese lung cancer patients. Cancer Science. 98(11). 1747–1751. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact